BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34239270)

  • 1. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy.
    Galanopoulos M; Doukatas A; Gkeros F; Viazis N; Liatsos C
    World J Gastroenterol; 2021 Jun; 27(24):3568-3580. PubMed ID: 34239270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.
    Rouanet M; Lebrin M; Gross F; Bournet B; Cordelier P; Buscail L
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.
    Sato-Dahlman M; Yamamoto M
    Curr Cancer Drug Targets; 2018; 18(2):153-161. PubMed ID: 28228084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic gene editing: delivery and regulatory perspectives.
    Shim G; Kim D; Park GT; Jin H; Suh SK; Oh YK
    Acta Pharmacol Sin; 2017 Jun; 38(6):738-753. PubMed ID: 28392568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
    Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
    Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in CRISPR/Cas9 Delivery Strategies.
    Yip BH
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Promise of Gene Therapy for Pancreatic Cancer.
    Vassaux G; Angelova A; Baril P; Midoux P; Rommelaere J; Cordelier P
    Hum Gene Ther; 2016 Feb; 27(2):127-33. PubMed ID: 26603492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer.
    Xu C; Sun Y; Wang Y; Yan Y; Shi Z; Chen L; Lin H; Lü S; Zhu M; Su C; Li Z
    Cancer Lett; 2012 Jun; 319(2):154-163. PubMed ID: 22261331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors.
    Dalba C; Klatzmann D; Logg CR; Kasahara N
    Curr Gene Ther; 2005 Dec; 5(6):655-67. PubMed ID: 16457654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
    Cervera-Carrascon V; Havunen R; Hemminki A
    Expert Opin Biol Ther; 2019 May; 19(5):443-455. PubMed ID: 30905206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent development of gene therapy for pancreatic cancer using non-viral nanovectors.
    Liu Y; Wu W; Wang Y; Han S; Yuan Y; Huang J; Shuai X; Peng Z
    Biomater Sci; 2021 Oct; 9(20):6673-6690. PubMed ID: 34378568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.